How FDA Approved Cannabis Products Could Affect CBD Distribution Channels

Last week, GW Pharma (NASDAQ: GWPH) scored a milestone victory, as the thirteen-member panel at the Peripheral and Central Nervous System Drugs Advisory Committee, which met on April 19th to consider the safety and efficacy of Epidiolex, its CBD-based product, and pass along its conclusions to the FDA, gave it a unanimous decision in favor of Epidiolex. The committee, which referred to Epidiolex as “Cannibidiol Oral Solution” (CBD-OS), saw it as safe and efficacious in treating seizures in patients 2 years of age and older suffering from Lennox-Gastaut syndrome and Dravet syndrome. The FDA is expected to complete its review process of the Epidiolex New Drug Application by June 27th. If approved, Epidiolex will be the first cannabis-derived FDA-drug approved.


Attorney Bob Hoban of Hoban Law Group sees limited impact to dispensaries selling cannabis-based products or to sellers of CBD from industrial hemp.

"As the first marijuana-derived drug set to be approved by FDA, the cannabis industry should closely monitor the progress of FDA’s review of Epidiolex," said Hoban. "Given that the state-legal marijuana industry exists in violation of federal law already, the federal approval of Epidiolex should have little immediate impact on these businesses."